Market intelligence, trend analysis and forecasts for the Pharma and Healthcare industries across the regions

Companies / Italy

Sales Stagnate For Recordati

February 2007 | Company Finance Alert

Italian drugmaker Recordati has reported flat revenues for 2006, with turnover reaching EUR576.2mn (US$757.3mn) form a figure of EUR576.1mn (US$757.2mn) in 2005, primarily due to a 7.8% fall in domestic sales. However, the company managed to post a double-digit increase in earnings, with net income rising 14.7% to EUR74mn (US$97.2mn). Recordati claims that increased profitability has primarily been due to the success of its flagship hypertension treatment Zanidip (lercanidipin), and 'the careful management of the company's resources'.

Sorry, you must be a subscriber to view this article in full. If you are a subscriber please login.

[
: *
[
: *


If you would like to subscribe to Western Europe Pharma & Healthcare Insight and gain instant access to this article, please click here to subscribe.

If you would like to take a trial to Western Europe Pharma & Healthcare Insight please click on the trial link below.

Free Trial To Pharmaceuticals & Healthcare Insight

TAKE A TRIAL >>
Western Europe InsightWestern Europe Channels Western Europe Countries